



Fig. 1



* : p < 0.05


Best Available Copy

Fig. 2



F4/80: staining by microglia cell-specific antibody
RCA-1: Ricinus communis agglutinin-1 lectin


F i g . 3



GFAP: staining by astroglia-specific antibody

4/26

Fig. 4




5/26

F i g . 5

Control




Onset




6/26

Fig. 6






7/26

Fig. 7



8/26


Fig. 8



stained with hematoxylin-eosin

9/26


Fig. 9



stained with H-PGDS-specific antibody




10/26

Fig. 10



GFAP : stained with astroglia-specific antibody

F i g . 1 1




HE: stained with hematoxylin-eosin

GFAP: stained with astroglia-specific antibody

DPR: stained with DP receptor-specific antibody

12/26

Fig. 12




HE: stained with hematoxylin-eosin

GFAP: stained with astroglia-specific antibody

F4/80: stained with microglia cell-specific antibody

Fig. 13




CML: cerebellum molecular layer

CGL: cerebellum granular layer

CWM: cerebellum white matter


GFAP: stained with astroglia-specific antibody

F i g . 1 4



F i g . 1 5

Administered with HQL-79



(stained with hematoxylin-eosin)

Control






Fig. 16



HE: stained with hematoxylin-eosin

GFAP: stained with astroglia-specific antibody

F i g . 1 7



HE: stained with hematoxylin-eosin

GFAP: stained with astroglia-specific antibody

Fig. 18





Fig. 19



19/26

Fig. 20






Fig. 21



F i g . 2 2



HE: stained with hematoxylin-eosin
GFAP: stained with astroglia-specific
antibody

22/26

F i g. 2 3




Fig. 24






Fig. 25

Control




administered with pinagladin

Before 1 hr and after 1 day



After 3 hrs and after 1 day



(stained with hematoxylin-eosin)

Fig. 26





Fig. 27



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☒ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.